Navigation Links
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:11/1/2008

N A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON.

The following serious or clinically significant adverse events have been reported at a frequency less than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages, and cotton wool spots.

In the PEGINTRON/REBETOL combination trial, the incidence of serious adverse events was 17% in the PEGINTRON/REBETOL groups compared to 14% in the INTRON A/ REBETOL group. The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23% in the INTRON A/REBETOL group and 31-34% in the PEGINTRON/REBETOL groups. Dose reductions due to adverse reactions occurred in 42% of patients receiving PEGINTRON (1.5 mcg/kg)/REBETOL and in 34% of those receiving INTRON A/REBETOL.

In a study with weight-based ribavirin, there was a higher rate of anemia among patients in the weight-based dosing group (29%) compared to the flat-dosing group (19%). The majority of these cases were mild and responded to dose reductions. Serious adverse events were similar between the two groups (12%), and discontinuations for adverse events (15% in weight-based dosing and 14% in flat dosing) were also similar. Dose modifications due to adverse events occurred more frequently in the weight-based dosing group (29%) compared to the flat-dosing (23%) group.

Additional Safety Information

Relapse of drug addiction/over
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
2. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
3. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
5. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
6. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , August 28, 2015 According ... by Tumor (Breast, Lung, Prostate) Type (Protein & Genetic ... Drug Discovery, Prognostic) & Geography - Global Forecast to ... expected to reach around 17,689.0 Million USD by 2020 ... of 2015 to 2020. Browse 191 ...
(Date:8/28/2015)... -- Research and Markets ( ... "12th Annual Report and Survey of Biopharmaceutical ... offering. The 2015 12th Annual Report ... is the most recent study of biotherapeutic developers ... capacity and production. The report contains the industry,s ...
(Date:8/28/2015)... 28, 2015 Patterson Medical, formerly the ... PDCO ), is now an independent company with ... Patterson Medical by Madison Dearborn Partners (MDP).  ... for a transition period before rebranding as the ... medicine products.  With the focused resources and expertise ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 512th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... BRUNSWICK, N.J. and LEIDEN, Netherlands, Feb. 8, 2011 Johnson ... (NYSE Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) ... Crucell. Reference is made to the joint press ... 8 December 2010 announcing the recommended cash offer by Johnson ...
... County Hospital is moving its computerization initiatives forward ... ChartAccess® Comprehensive EHR, the 20-bed hospital is planning ... requirements as stipulated under the American Recovery and ... same time, the Ness City, Kan.-based provider continues ...
Cached Medicine Technology:Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters 2Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters 3Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters 4Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters 5Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters 6Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters 7Ness County Hospital Selects ChartAccess® Comprehensive EHR from Prognosis Health Information Systems 2Ness County Hospital Selects ChartAccess® Comprehensive EHR from Prognosis Health Information Systems 3
(Date:8/30/2015)... ... , ... Certified Nutrition Businessman Reid Eckert agrees to extend his business relationship ... global sales and communications firm that offers U.S. brands a proven path to world ... Mr. Reid Eckert, as his interpretation of the nutritional needs of the human body ...
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College ... serve as the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who ... help the college expand its reach and impact through innovative technologies and strategies. , ...
(Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... 1996," said one of two inventors from Miller Place, N.Y. "I specialize in ... pain and discomfort. In addition, it can be used for additional muscle dysfunction ...
(Date:8/29/2015)... ... ... like Toppik , Eau Thermale Avene and Bliss are now available on ... required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations manager. ... the item’s selling price.” , With competitive pricing in the e-commerce market for beauty ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain have ... soft tissue manipulation. Platelet rich plasma injections also have mixed results. Building ... treatment outcomes. This localized treatment seems to address the symptoms and does ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... consumers are good judges of affordability, but a new study ... by whether you think about a larger pool of resources ... cash in your wallet). Through a series of four ... food and time. Counting calories" Youre more likely to eat ...
... the University of California San Francisco has identified distinct ... is likely to develop subsequent invasive cancer after initial ... The research, published by Cell Press in the November ... be used to determine whether a woman should receive ...
... Shopko announced today the,appointment of W. Paul ... Officer. Jones will be responsible for the direction ... mass retailer. Jones, career has been highlighted ... mid-tier chain stores and big box retailers. He,has ...
... scientists,from around the world gathered for the 2007 ... The Symposium was,hosted by the Ringling Bros. and ... International Elephant Foundation (IEF), and was,held in conjunction ... Research. The Conference brought together experts in human ...
... releases nationwide eValue8,findings, SCOTTSDALE, Ariz., Nov. ... of health plan performance released today by ... health plans could do a,better job of ... in patient safety, care coordination, consumer selection ...
... Barry McMillen - Nicotine Cessation Expert and ... ... Using tobacco isn,t just a,habit; it,s an addiction. Hazelden has been ... years. The same principles,of the Hazelden treatment experience help tobacco users ...
Cached Medicine News:Health News:Big ticket: You'll spend more thinking about your bank account than about your wallet 2Health News:Biomarkers predict risk for invasive breast cancer years before the tumor develops 2Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 2Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 3Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 4Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 2Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 3Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 4Health News:Quit Smoking Tips For The Great American Smokeout Day - November 15 2
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
... Shuttle Relay Suture Passer allows braided suture ... repair procedures. It may be used ... material and in conjunction with anchors or ... Additionally, the Shuttle Relay can be ...
... Medical Record organizes communication and chart ... outside practitioners. It also manages orders, ... data that traditionally rely on many ... chart. With Microsoft Outlook integration, HealthMatics ...
Medicine Products: